-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Graves' Ophthalmopathy Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Myasthenia Gravis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Myasthenia Gravis Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Brivaracetam in Childhood Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brivaracetam in Childhood Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brivaracetam in Childhood Epilepsy Drug Details: Brivaracetam (Briviact / Brivlera) the 4-n-propyl...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Demyelinating Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Demyelinating Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Demyelinating Diseases Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTI-101 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TTI-101 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TTI-101 in Colorectal Cancer Drug Details: TTI-101 is under development for...
-
Thematic Analysis
Power M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Power Sector
-
Sector Analysis
Colorectal Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
Colorectal Cancer Market Report Overview The colorectal cancer market sales across the 8MM were estimated at $15.8 billion in 2021. The market is expected to achieve a CAGR of more than 3% during 2021-2031. The global growth is driven by the anticipated approval and launch of 14 pipeline therapies and the label expansions of other agents. Colorectal cancer Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Colorectal cancer Market Forecast Download A Free Report...
-
Sector Analysis
Major Depressive Disorder in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2029
Major Depressive Disorder Market Report Overview The major depressive disorder (MDD) market sales across the 8 major markets (MM) were valued at $4.73 billion in 2019. The market is expected to achieve a CAGR of more than 7% during 2019-2029. The US market makes up the most total global sales due to the large MDD prevalent population, combined with the high price of medication in the country. Major Depressive Disorder Market Outlook, 2019-2029 ($ Billion) Buy the Full Report to...